• October 19, 2026
Bausch + Lomb Appoints Thomas J. Appio as Interim Chief Executive Officer

Bausch + Lomb Corporation and its parent company, Bausch Health Companies Inc announced that Bausch…

  • October 12, 2026
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Corporation announced progress in the development of BL1243 (tonabersat), an investigational oral…

  • October 5, 2026
Bausch + Lomb Review Examines Artificial Tear Selection for Personalized Dry Eye Management

Bausch + Lomb announced the publication of a comprehensive review article examining tear film structure…